6534-28-7Relevant articles and documents
Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives
-
Page 9, (2008/06/13)
This invention relates to novel anthraquinone compounds useful in the treatment of allergic, inflammatory conditions, antioxidant, tumor condition, stem cell application, tissue engineering, applied in treating age-associate tissue degeneration, reverse organ failure in chronic high-turnover disease and therapeutic compositions containing such compounds. The compounds of the present invention are 1,4-, 1,5- and 1,8-difunctionalized anthraquinones or analogs thereof. According to the practice of the invention, there are provided bis-symmetrical substituted anthraquinone compounds according to formula I: wherein R1, R2, R3 and R4 present a straight, aminoalkylamino side chains or branched chain alkyl group having 1 to 6 carbons which may be substituted with one or more groups of R5, or R1, R2, R3 and R4 present phenyl or benzyl which may be substituted with one or two groups of R6; wherein R5 is selected from the group consisting of halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, and —OCH2CH2CH3; and wherein R6 is selected from the group consisting of a straight or branched chain alkyl group having 1 to 4 carbons, halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, —OCH2CH2CH3, —CH2Br, —CH2Cl, —CH2OH, —C(CH3)3, —(CH2)20H, —(CH2)3OH, —(CH2)4OH, —CH2NH2, —(CH2)2NH2, —(CH2)3NH2, —(CH2)4NH2, —(CH2)5NH2, —CH2N(CH3)2, —(CH2)2N(CH3)2, —(CH2)2NH(CH2)2OH, —(CH2)3NH(CH2)2OH, —(CH2)2NHCH2OH, —(CH2)3NHCH2OH, —CH2CH(CH3)2, —CHCl2, —CH(CH3)Cl, —(CH2)2Cl, —(CH2)3Cl, —(CH2)3Br, —(CH2)4Br, and —(CH2)4Cl. Chart 1. Activation of hTERT promoter-driven SEAP expression by c-Myc. About 1×107 hTERT-BJ1 cells were transfected with 13.5 μg each of plasmid pSEAP or pPhTERT-SEAP and of plasmid pMT2T or pMT2T-cMyc by electroporation. After 24 h, viable cells were harvested, and reinoculated at a density of 3×105/mL, and the SEAP activity after 24 h at 37 □. The transfection efficiency of each experiment was determined by cotransfection with 1.5 μg of plasmid pCMVβ. The values were determined from three experiments. P0.05 is presented by an asterisk.
Synthesis and cytotoxic evaluation of two novel anthraquinone derivatives
Sadeghi-Aliabadi, Hojjat,Tabarzadi, Maryam,Zarghi, Afshin
, p. 645 - 649 (2007/10/03)
The antitumor activity of dihydroxyanthracenediones such as mitoxantrone on a panel of cancer cell lines during the last 30 years, led investigators to synthesize thousands of anthracycline analogs and test their cytotoxicity to identify compounds superior to the parent drugs in terms of increased therapeutic effectiveness, reduced toxicity or both. To achieve this, new synthesized congeners either have different side arms or have extra rings on their skeletons. Following these studies, we proposed total synthesis of 2-amino-N-[4-(2-amino-3-hydroxy-propionylamino)-9,10-dioxo-9, 10-dihydroanthracene-1-yl]-3-hydroxy-propionamide (V) and 6-amino-hexanoic acid [4-(5-amino-pentanoylamino)-9,10-dioxo-9,10-dihydro-anthracen-1-yl]-amide (VI). Acetylation of 1,4-diaminobenzene using acetyl chloride and reaction with phthalic anhydride under a Friedel-Crafts reaction and then cyclization gave 1, 4-diamino-anthraquinone. This compound was reacted with two amino acids (L-serine and 6-amino hexanoic acid) in their ester forms, using ethyl chloroformate as a coupling agent. Hydrolyzing esterified compounds gave their amino substituted derivatives. These compounds with diamine side arms are supposed to provide better intercalation with DNA. Synthesized novel ametantrone derivatives were tested against a panel of cancer cells (KB, Hela, MDA-MB-468 and K562), using MTT assay. The results showed that tested compounds inhibited the growth of cancer cells at micromolar concentrations. However, compound (VI) was more cytotoxic than compound (V) probably because of its longer side chains and better intercalation with DNA.
